Leaderboard
Insiders and issuers ranked by realized signed return on open-market Form 4 trades. Returns are signed: a sale followed by a rally counts against the seller.
What the metrics mean
Return - the insider's signed return per trade, averaged. A +10% stock move on a buy scores +10%; on a sell, -10%. Because most insider activity is concentrated at rallying stocks, this metric correlates with raw stock performance and doesn't fully isolate timing skill from market drift.
Edge - signed return minus the stock's average forward N-day return over the same period. An insider with +5% edge consistently chose better days to trade than someone who'd picked a random day in the same window. Isolates timing skill from "the stock just went up."
Neither metric is the same as ranking stocks by raw return - that would just surface the best-performing tickers, which you can get from any market screener.
Insiders ranked
213
Showing 50 of 213
Quality filters
10+ trades
≥3 issuers, 50% price coverage
Window
5y trailing
Trade date filter
| # | Insider | Trades | Issuers | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|---|
| 1 | Seidenberg Beth C | 20/23 | 4 | 95% | +454.9% | +481.1% | +578.7% | -78.7% |
| 2 | Topper James N | 11/21 | 6 | 82% | +175.6% | +249.4% | +301.5% | -55.0% |
| 3 | Edelman Joseph | 49/77 | 15 | 61% | +171.2% | +82.0% | +871.3% | -90.9% |
| 4 | Perceptive Advisors LLC | 49/77 | 15 | 61% | +171.2% | +82.0% | +871.3% | -90.9% |
| 5 | Perceptive Life Sciences Master Fund Ltd | 49/64 | 14 | 61% | +171.2% | +82.0% | +871.3% | -90.9% |
| 6 | Corre Partners Management, LLC | 46/70 | 3 | 76% | +160.4% | +172.4% | +343.9% | -60.2% |
| 7 | Levinson Sam | 12/17 | 3 | 58% | +142.7% | +107.4% | +394.0% | -52.6% |
| 8 | Horowitz Joshua | 22/27 | 4 | 64% | +111.0% | +136.3% | +291.8% | -49.8% |
| 9 | Nodelman Oleg | 30/32 | 4 | 90% | +105.5% | +103.9% | +266.2% | -13.6% |
| 10 | Whitmore Bradford T | 37/66 | 3 | 78% | +105.4% | +20.9% | +454.9% | -24.8% |
| 11 | Gibson Daniel Patrick | 35 | 3 | 91% | +104.6% | +117.5% | +226.2% | -18.0% |
| 12 | Sylebra Capital Ltd | 25 | 3 | 88% | +102.4% | +122.2% | +176.6% | -18.0% |
| 13 | 325 Capital LLC | 37 | 3 | 95% | +96.7% | +103.3% | +125.0% | -14.3% |
| 14 | Braner Michael David | 37 | 3 | 95% | +96.7% | +103.3% | +125.0% | -14.3% |
| 15 | Shrivastava Anil K | 37 | 3 | 95% | +96.7% | +103.3% | +125.0% | -14.3% |
| 16 | Sylebra Capital LLC | 13/18 | 3 | 100% | +89.3% | +88.0% | +226.2% | +2.6% |
| 17 | Ecor1 Capital, LLC | 60/66 | 9 | 92% | +83.2% | +86.1% | +266.2% | -42.4% |
| 18 | Friedberg Daniel M. | 46/48 | 4 | 91% | +82.9% | +97.0% | +125.0% | -71.1% |
| 19 | Heron Patrick J | 26/34 | 5 | 96% | +77.8% | +75.7% | +249.4% | -55.0% |
| 20 | Casdin Capital, LLC | 44/75 | 4 | 43% | +68.0% | -18.3% | +1106.3% | -64.8% |
| 21 | Casdin Eli | 44/78 | 4 | 43% | +68.0% | -18.3% | +1106.3% | -64.8% |
| 22 | Casdin Partners Gp, LLC | 44/75 | 4 | 43% | +68.0% | -18.3% | +1106.3% | -64.8% |
| 23 | Casdin Partners Master Fund, L.P. | 44/75 | 4 | 43% | +68.0% | -18.3% | +1106.3% | -64.8% |
| 24 | Cummins Wes | 47/53 | 3 | 72% | +60.1% | +47.2% | +240.5% | -48.1% |
| 25 | Demichele Michael | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 26 | Mfn Partners Gp, LLC | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 27 | Mfn Partners Management, LLC | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 28 | Mfn Partners Management, LP | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 29 | Mfn Partners, LP | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 30 | Nanji Farhad | 36/37 | 3 | 58% | +59.1% | +9.2% | +858.8% | -46.2% |
| 31 | Strobeck Matthew | 16/24 | 4 | 63% | +59.0% | +100.8% | +135.0% | -67.9% |
| 32 | Biotechnology Value Fund II LP | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 33 | Biotechnology Value Fund L P | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 34 | Bvf Gp Holdings LLC | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 35 | Bvf I Gp LLC | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 36 | Bvf II Gp LLC | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 37 | Bvf Inc/Il | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 38 | Bvf Partners L P/Il | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 39 | Bvf Partners Os Ltd. | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 40 | Biotechnology Value Trading Fund Os LP | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 41 | Lampert Mark N | 56/90 | 7 | 55% | +50.5% | +5.8% | +284.7% | -16.3% |
| 42 | Icahn Carl C | 109/117 | 6 | 98% | +47.3% | +39.7% | +102.6% | -20.7% |
| 43 | Wallman Richard F | 10/20 | 3 | 100% | +46.2% | +16.3% | +158.2% | +3.3% |
| 44 | Horizon Kinetics Asset Management LLC | 2,798/3,145 | 3 | 70% | +44.0% | +22.3% | +203.4% | -49.3% |
| 45 | Forager Fund, L.P. | 15/30 | 4 | 100% | +34.2% | +42.0% | +82.7% | +3.7% |
| 46 | Kissel Edward Urban | 15/30 | 4 | 100% | +34.2% | +42.0% | +82.7% | +3.7% |
| 47 | MacArthur Robert Symmes | 15/30 | 4 | 100% | +34.2% | +42.0% | +82.7% | +3.7% |
| 48 | Breber Pierre R | 21/23 | 3 | 95% | +33.0% | +36.5% | +36.5% | -32.5% |
| 49 | Va Partners I, LLC | 32/33 | 3 | 100% | +31.9% | +29.6% | +52.4% | +11.8% |
| 50 | Valueact Capital Management, L.P. | 32/33 | 3 | 100% | +31.9% | +29.6% | +52.4% | +11.8% |
Showing 1-50 of 213